Title | Paired exome analysis of Barrett's esophagus and adenocarcinoma. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ |
Journal | Nat Genet |
Volume | 47 |
Issue | 9 |
Pagination | 1047-55 |
Date Published | 2015 Sep |
ISSN | 1546-1718 |
Keywords | Adenocarcinoma, Barrett Esophagus, Class I Phosphatidylinositol 3-Kinases, Cyclin-Dependent Kinase Inhibitor p16, DNA Mutational Analysis, Esophageal Neoplasms, Exome, Gene Amplification, Gene Frequency, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Phosphatidylinositol 3-Kinases, Point Mutation, Tumor Suppressor Protein p53 |
Abstract | Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) through a stepwise progression with loss of CDKN2A followed by TP53 inactivation and aneuploidy. Here we present whole-exome sequencing from 25 pairs of EAC and Barrett's esophagus and from 5 patients whose Barrett's esophagus and tumor were extensively sampled. Our analysis showed that oncogene amplification typically occurred as a late event and that TP53 mutations often occurred early in Barrett's esophagus progression, including in non-dysplastic epithelium. Reanalysis of additional EAC exome data showed that the majority (62.5%) of EACs emerged following genome doubling and that tumors with genomic doubling had different patterns of genomic alterations, with more frequent oncogenic amplification and less frequent inactivation of tumor suppressors, including CDKN2A. These data suggest that many EACs emerge not through the gradual accumulation of tumor-suppressor alterations but rather through a more direct path whereby a TP53-mutant cell undergoes genome doubling, followed by the acquisition of oncogenic amplifications. |
DOI | 10.1038/ng.3343 |
Alternate Journal | Nat Genet |
PubMed ID | 26192918 |
PubMed Central ID | PMC4552571 |
Grant List | L30 CA179766 / CA / NCI NIH HHS / United States U54 HG003067 / HG / NHGRI NIH HHS / United States T32 HL007627 / HL / NHLBI NIH HHS / United States U54 CA163059 / CA / NCI NIH HHS / United States K08 CA134931 / CA / NCI NIH HHS / United States K07 CA151613 / CA / NCI NIH HHS / United States T32 CA009676 / CA / NCI NIH HHS / United States P50CA127003 / CA / NCI NIH HHS / United States P01 CA098101 / CA / NCI NIH HHS / United States U54 HG0003067 / HG / NHGRI NIH HHS / United States P50 CA127003 / CA / NCI NIH HHS / United States T32 GM007748 / GM / NIGMS NIH HHS / United States U54 CA163004 / CA / NCI NIH HHS / United States |
Related Faculty:
Massimo Loda, M.D.